Apellis Pharmaceuticals, Inc.

APLSNASDAQHealthcare

$41.03

+$0.00(+0.00%)

Market Cap$5.3B

P/E Ratio—

52W High$41.14

52W Low$16.61

Avg Volume6.4M

Open$41.05

Beta-0.25

Net Income Financials Revenue

Apellis Pharmaceuticals, Inc. (APLS) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

APLS · net income · updated Jun 8, 2026

Core profitability metrics

APLS · net income · margin · TTM · CAGR

Net income was $22.4M for FY2025 (fiscal year ending 2025-12-31), up 111.3% year-over-year. Net profit margin was 2.2%. Based on available data, Apellis Pharmaceuticals, Inc. has been profitable since at least 2025.

FY2025 Net Income$22.4M▲ +111.3% YoY

Trailing 12M (TTM)$133.3Mtrailing 4 quarters sum

Net Profit Margin2.2%$22.4M ÷ $1.00B

YoY Change+111.3%—

5-Year CAGRN/AN/A — contains loss years

FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /income-statement · US GAAP · USDUpdated: Jun 8, 2026

Annual net income history

Net Income (bars) · Net Profit Margin % (line)

Net IncomeNet LossNet Margin %★ First Profit: 2025

▸ FMP /income-statement · Annual · APLS net income history · APLS profit margin

Annual net income data

APLS · net income history · annual / quarterly

Fiscal YearNet IncomeYoY ChangeNet MarginRevenue

FY2025★ First Profit$22.4M▲ +111.3%2.2%$1.00B

FY2024Loss−$197.9M▲ +62.6%-25.3%$781.4M

FY2023Loss−$528.6M▲ +18.9%-133.3%$396.6M

FY2022Loss−$652.2M▲ +12.6%-864.7%$75.4M

FY2021Loss−$746.4M▼ 116.4%-1121.3%$66.6M

Net income vs peers (Healthcare)

APLS vs peers · net income

#CompanyNet IncomeYoYNet MarginRelative

Apellis Pharmaceuticals, Inc.YOU

APLS

$22.4M+111.3%2.2%

Eli Lilly and Company

LLY

$20.64B+94.9%31.7%

77%

UnitedHealth Group Incorporated

Healthcare · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

Apellis Pharmaceuticals, Inc. (APLS) reported net income of $22.4M for FY2025 (fiscal year ending 2025-12-31), up 111.3% year-over-year. The net profit margin was 2.2% — meaning the company kept $0.02 of every dollar of revenue as profit.

Based on available data, Apellis Pharmaceuticals, Inc. has been profitable since at least 2025. Net income reached a peak of $22.4M in FY2025. Data available for 13 fiscal years.

Apellis Pharmaceuticals, Inc.'s net profit margin was 2.2% for FY2025, based on the latest annual results.

Investors sometimes search for "Apellis Pharmaceuticals, Inc. net worth" — the company's market capitalization is a separate figure from APLS net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.

Revenue Financial statements Earnings Forecast Price history Market cap Free cash flow

Frequently asked questions

APLS net income · 5 questions

Apellis Pharmaceuticals, Inc. is profitable. The company reported net income of $22.4M for FY2025, a net profit margin of 2.2%. Net income was up 111.3% year-over-year. Based on available data, Apellis Pharmaceuticals, Inc. has been profitable since at least 2025.

is APLS profitabledoes APLS make a profitAPLS profitabilityAPLS profitable company

▸ Source: FMP /income-statement · GAAP · Apellis Pharmaceuticals, Inc. · Apellis Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026